Proactive Investors - Run By Investors For Investors

ReNeuron enjoys “transformational” year; eye disease trial data due in October

ReNeuron’s progress over the past year has been reflected in its share price, which has trebled since last March – the beginning of the company’s financial year
All eyes will be on the American Academy of Ophthalmology Annual Meeting in October

Bosses at cell-based therapeutics specialist ReNeuron Group PLC (LON:RENE) have described the past 12 months as “transformational”.

The highlight of the Neil Woodford-backed company’s year came in February, when it reported positive initial data from the mid-stage study of its retinitis pigmentosa treatment.

WATCH: ReNeuron encouraged by level of interest in its key programmes

After being treated with ReNeuron’s human retinal progenitor cells (hRPC), the first three patients were able to read an additional three lines of the standard ETDRS eye chart.

Even chief financial officer Michael Hunt was amazed, telling Proactive at the time that to see such strong reactions in every patient that had been treated so far was “very surprising”.

After the end of the company’s financial year, ReNeuron reported that those initial improvements seen in the early patients had been sustained and actually enhanced as the study progressed.

Chinese giant Fosun liked what it saw

Top-line results for all patients are due to be presented at the American Academy of Ophthalmology Annual Meeting in October.

The trial’s progress helped to catch the eye of Chinese drugs giant Fosun Pharma, which, in April, agreed to license ReNeuron’s hRPC and its CTX stem cell therapy for stroke as part of a deal worth up to £80mln.

Speaking of CTX, a phase IIb trial kicked off in the US at the beginning of 2019, and top-line data from that is due in late 2020.

More data readouts due over next 18 months

“The past year has been a transformational one for ReNeuron,” said chief executive Olav Hellebø.

“During the period, we commenced patient dosing in the US placebo-controlled Phase 2b clinical trial of our CTX cell therapy candidate in chronic stroke disability.

“This was followed shortly afterwards by the announcement of strongly positive preliminary efficacy data from the first three phase IIa patients in the ongoing US phase I/IIa clinical trial of our hRPC cell therapy candidate in retinitis pigmentosa.”

He added: “We look forward to delivering further significant clinical data in our stroke and retinitis pigmentosa programmes over the next 18 months.”

Full-year loss narrows

Losses fell to £14.3mln in the 12 months to the end of March (2018: loss of £17.6mln).

At the end of period, ReNeuron had cash and cash equivalents of £26.4mln (2018: £37.4mln), although this doesn’t include the £5.4mln upfront payment received from Fosun in April.

Shares were down 8% to 253p in early deals on Thursday.

View full RENE profile View Profile

ReNeuron Group PLC Timeline

Related Articles

Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use